Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Companies Get Yet More Time To Assess Nitrosamine Risk In EU

Deadline For Assessing Chemical Medicines Extended Until 31 March 2021

Aug 07 2020

• By Vibha Sharma

Nitrosodimethylamine — Nitrosamines are classified as probable human carcinogens • Source: Shutterstock

Related Content

More Time For EU Nitrosamine Evaluations Due To COVID-19

Mar 27 2020

Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation

Jul 13 2020

The EU's Top Valsartan Lesson: Closely Examine Active Substance Manufacturing Processes

Jun 26 2020

Nitrosamine Episode Could Lead To Paradigm Shift In Quality

Oct 10 2019

Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators

Dec 09 2019

Additional Topics

Europe Manufacturing Regulation Safety Drug Safety BioPharmaceutical

More from Europe

More from Geography

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.